

Ilumya[™] (tildrakizumab-asmn) – New drug approval

- On March 21, 2018, <u>Sun Pharma announced</u> the FDA approval of <u>Ilumya (tildrakizumab-asmn)</u> for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Psoriasis is a chronic immune disease that appears on the skin. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form, affecting about 80% to 90% of people living with psoriasis, is called plaque psoriasis.
- Ilumya selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines.
- The efficacy and safety of Ilumya were demonstrated in two placebo-controlled studies of 926 patients with plaque psoriasis. The co-primary endpoints were the proportion of patients who achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) composite score and the proportion of patients with a Physician Global Assessment (PGA) of 0 or 1 and at least a 2-point improvement at week 12.
 - Both clinical studies demonstrated improvements with Ilumya in the primary endpoints vs. placebo (PASI 75: 64% and 61% vs. 6% in both studies; PGA of 0 or 1: 58% and 55% vs. 7% and 4%, respectively).
- Warnings and precautions of Ilumya include hypersensitivity, infections, pretreatment evaluation for tuberculosis, and immunizations.
- The most common adverse reactions (≥ 1%) with Ilumya use were upper respiratory infections, injection site reactions, and diarrhea.
- The recommended dose of Ilumya is 100 mg administered by a healthcare provider as a subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter.
- Sun Pharma's launch plans for llumya are pending. llumya will be available as a 100 mg/mL solution in a single-dose prefilled syringe.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.